Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), John F. DiPersio(Washington University in St. Louis), Jan Davidson‐Moncada(MacroGenics (United States)), Ezio Bonvini(MacroGenics (United States)), Matteo Giovanni Carrabba(Vita-Salute San Raffaele University), Martha Arellano(Memorial Sloan Kettering Cancer Center), Kerri Cali(MacroGenics (United States)), Erin Timmeny(MacroGenics (United States)), Fabio Ciceri(Vita-Salute San Raffaele University), Sergio Rutella(Bambino Gesù Children's Hospital), Matthew C. Foster(University of North Carolina at Chapel Hill), Gerwin Huls(University Medical Center Groningen), Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), S. Church(Nanostring Technologies (United States)), Jayakumar Vadakekolathu(Nottingham Trent University), Jan Baughman(University of California System), Camille Poirot(Servier (France)), Bob Löwenberg(Unknown), Alessandra Cesano(Nanostring Technologies (United States)), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), John E. Godwin(Providence Portland Medical Center), Kendra Sweet(Moffitt Cancer Center), Michael P. Rettig, David A. Rizzieri(Duke University), John Muth(MacroGenics (United States)), Ross La Motte‐Mohs(MacroGenics (United States)), Kathy Tran(McGovern Institute for Brain Research), Giovanni Martinelli(University of Bologna), Teia Curtis(MacroGenics (United States)), Athanasios Pallis(Servier (France)), Max S. Topp(Universitätsklinikum Würzburg), Kang Yang(Wuhan University), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Jichao Sun(MacroGenics (United States)), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 40
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>Planck</i>2015 results
|Astronomy and Astrophysics|2016|10.7k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
<i>Planck</i>2013 results. XVI. Cosmological parameters
|Astronomy and Astrophysics|2014|6.6k